

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, with Express Mail Label No. EL523936059US on this date: 2-16-01 By: G. Barclay

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Guittard, George V., et al.

Serial No.: Not Assigned

Filed: Herewith

For: Method for the  
Management of  
Incontinence

Group Art Unit: Not Assigned

Examiner:

**Preliminary Amendment**

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir/Madam:

PRELIMINARY AMENDMENT

Please amend the application filed herewith as follows:

IN THE CLAIMS

Cancel claims 2-31.

Add new claims 32 and 33 as follows:

32. A pharmaceutical dosage form comprising 240 ng to 650 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salts, the dosage form being adapted to be administered once-a-day and release the member at a controlled and sustained rate.

33. The dosage form of claim 32 wherein the controlled and sustained rate is substantially zero order.

**IN THE SPECIFICATION**

On page 1, line 4, after "application" insert -- is a continuation of U.S. Patent Application Serial No. 09/280,309, filed March 29, 1999, now US Patent No. , which - -.


**REMARKS**

In accordance with usual practice, please calculate the filing fee in the above-identified accompanying application after cancellation of claims 2-31. Upon entrance of the amendment, claims 1 and 32-33 will be in the application.

The specification is being amended to identify the related parent application of which this application is a continuation.

Respectfully submitted,

Dated: 2-16-01

  
John A. Dhuey  
Registration Number 26,265  
Attorney for the Applicants

ALZA Corporation  
1900 Charleston Road  
P.O. Box 7210  
Mountain View, CA 94039-7210  
650-564-5699